Open Label Arm for Urinary Tract Infections, Recurrent

Phase-Based Progress Estimates
St. Joseph's Health Centre, Toronto, Canada
Urinary Tract Infections, Recurrent+3 More
Phage Therapy - Biological
What conditions do you have?

Study Summary

This is a single-patient, phase II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urinary tract infection with serious long-term effects. This study will follow a minimally invasive phage therapy approach consisting of oral, topical (opening of the urethra) and bladder installations of a 3-phage cocktail comprised of HP3, HP3.1 and ES19.

Eligible Conditions

  • Urinary Tract Infections, Recurrent

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Urinary Tract Infections, Recurrent

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 90 Days

90 Days
Clinical and microbial response
Safety and Tolerability

Trial Safety

Safety Progress

1 of 3

Other trials for Urinary Tract Infections, Recurrent

Trial Design

1 Treatment Group

Open Label Arm
1 of 1
Experimental Treatment

1 Total Participants · 1 Treatment Group

Primary Treatment: Open Label Arm · No Placebo Group · Phase < 1

Open Label Arm
Experimental Group · 1 Intervention: Phage Therapy · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days
Closest Location: St. Joseph's Health Centre · Toronto, Canada
Photo of Toronto  1Photo of Toronto  2Photo of Toronto  3
2011First Recorded Clinical Trial
1 TrialsResearching Urinary Tract Infections, Recurrent
26 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have had a diagnosis of recurrent chronic urinary tract infections with severe long term effects.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.